Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Saccardi, Riccardo  [Clear All Filters]
2024
Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, Angelillo P, Barbui AMaria, Cutini I, Dodero A, et al. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. Leukemia. 2024.
Mariottini A, Nozzoli C, Carli I, Landi F, Gigli V, Repice AMaria, Ipponi A, Cecchi M, Boncompagni R, Saccardi R, et al. Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis. Neurol Sci. 2024.
Greco R, Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, Sharrack B, Snowden JA, Tarte K, et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. EClinicalMedicine. 2024;69:102476.
Niederwieser C, Iacobelli S, Franke G-N, Koster L, van Os M, Platzbecker U, Hübel K, Scheid C, Müller LPeter, Stelljes M, et al. Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC). Bone Marrow Transplant. 2024.
2023
von Asmuth EGJ, Putter H, Mohseny AB, Schilham MW, Snowden JA, Saccardi R, Lankester AC. Automating outcome analysis after stem cell transplantation: The YORT tool. Bone Marrow Transplant. 2023.
Saccardi R, Putter H, Eikema D-J, Busto MPaula, McGrath E, Middelkoop B, Adams G, Atlija M, Ayuk FAyuketang, Baldomero H, et al. Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2023.
Cseh A, Galimard J-E, De La Fuente J, Isgrò A, Zecca M, Garwer B, Biffi A, Aljurf M, Sundin M, Belendez C, et al. Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties. Br J Haematol. 2023.
Baron F, Ruggeri A, Peczynski C, Labopin M, Bourhis J-H, Michallet M, Chevallier P, Sanz J, Forcade E, Saccardi R, et al. Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2023.
Mina R, Petrucci MTeresa, Bonello F, Bongarzoni V, Saccardi R, Bertuglia G, Mengarelli A, Spadaro A, Lisi C, Curci P, et al. A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents. Haematologica. 2023.
Mariottini A, Muraro PA, Saccardi R. Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis?. Mult Scler Relat Disord. 2023;78:104932.
2022
Mariottini A, Bulgarini G, Forci B, Innocenti C, Mealli F, Mattei A, Ceccarelli C, Repice AMaria, Barilaro A, Mechi C, et al. Autologous hematopoietic stem cell transplantation vs low-dose immunosuppression in secondary-progressive multiple sclerosis. Eur J Neurol. 2022.
Lunetta C, Lizio A, Cabona C, Gerardi F, Sansone VAda, Corbo M, Scialò C, Angelucci E, Gualandi F, Marenco P, et al. A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis. J Neurol. 2022.
2020
Sheth V, Volt F, Sanz J, Clement L, Cornelissen J, Blaise D, Sierra J, Michallet M, Saccardi R, Rocha V, et al. Reduced-intensity versus myeloablative conditioning in cord blood transplantation for AML (40-60 years) across highly mismatched HLA barriers - On behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT. Biol Blood Marrow Transplant. 2020.
Shouval R, Labopin M, Bomze D, Baerlocher GM, Capria S, Blaise D, Hänel M, Forcade E, Huynh A, Saccardi R, et al. Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. Bone Marrow Transplant. 2020.
2019
Shouval R, Labopin M, Gorin NC, Bomze D, Houhou M, Blaise D, Zuckerman T, Baerlocher GM, Capria S, Forcade E, et al. Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia. Cancer. 2019.
Irdani T, Mazzanti B, Ballerini L, Saccardi R, Torre R. A non-traditional approach to cryopreservation by ultra-rapid cooling for human mesenchymal stem cells. PLoS One. 2019;14(7):e0220055.
Candoni A, Rambaldi A, Fanin R, Velardi A, Arcese W, Ciceri F, Lazzarotto D, Lussana F, Olivieri J, Grillo G, et al. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Societ. Biol Blood Marrow Transplant. 2019.
2018
Mariottini A, Innocenti C, Forci B, Magnani E, Mechi C, Barilaro A, Nistri R, Fani A, Saccardi R, Massacesi L, et al. Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis. Eur J Neurol. 2018.
2016
Mazzanti B, Urbani S, Dal Pozzo S, Bufano P, Ballerini L, Gelli A, Sodi I, Donnini I, Di Gioia M, Guidi S, et al. Fully automated, clinical-grade bone marrow processing: a single-centre experience. Blood Transfus. 2016:1-8.
2015
Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M, Satsangi J, Danese S, et al. Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. JAMA. 2015;314(23):2524-2534.
2014
van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EWA, Vonk MC, Schattenberg AV, et al. Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial. JAMA. 2014;311(24):2490-2498.